|
Diabetes Medication Article
FDA's Role in Regulating Insulin
FDA's Center for Drug Evaluation and Research (CDER) oversees drug products, including insulin. CDER makes sure that drugs sold in the U.S. are safe and effective. The center evaluates new types of insulin products, and it regulates the manufacturing, labeling, and advertising of insulin products.
Companies wanting to market insulin products are responsible for testing their products and submitting data showing they are safe and effective. At CDER, teams of doctors, statisticians, and scientists review new drug applications (NDAs). In some cases, FDA seeks help from advisory committees made up of outside experts.
Once a new insulin product is on the market, CDER monitors its quality and makes sure that its manufacturer follows FDA laws and regulations. CDER also monitors insulin products carefully after they are approved to identify any unexpected side effects. Through a system called MedWatch, health professionals and consumers can report serious adverse reactions to any medical product. CDER collects information from MedWatch and the drug industry and conducts statistical evaluations on drug usage, adverse reactions, poisonings, safety, and effectiveness. If necessary, CDER shares information with patients and health professionals.
Diabetes Testing Center
Heart News Center
Hot Home Gym Reviews
The Secret Wisdom You Have Inside
Get Rid of Your Belly fat
Avandia Drug News
Avandia Drug
IMPORTANT: Bing News RSS feed has moved!
According to a report by Bloomberg News, the drug maker agreed to the Avandia settlements last month as part of court-ordered mediation. Glaxo has previously agreed to settle more than 15,000 Avandia lawsuits filed in state and federal courts throughout ...
Read moreAvandia Settlements Reached in Additional Lawsuits: Report
Pharmaceutical giant GlaxoSmithKline has agreed to settle about 20,000 heart attack lawsuits brought by former users of its Type 2 diabetes medication Avandia. The lawsuits are among thousands more which claim GlaxoSmithKline (GSK) hid data ...
Read moreAvandia Mediation Nets Settlement for 20,000 Heart Attack Lawsuits
will hire 20 people Life sciences materials distributor opens executive HQ office in Durham Follow this company has agreed to settle several product liability cases involving its blockbuster diabetes drug Avandia, spokeswoman Bernadette King ...
Read moreGlaxoSmithKline agrees to Avandia settlements
After a decade of drug safety crises where medicines have mostly either wound up yanked (Vioxx, Zelnorm) or close to it (Avandia), today’s news about the multiple sclerosis drug Tysabri is positively amazing. Biogen Idec Inc. (BIIB ...
Read moreTysabri: The Model For Facing A Drug Safety Crisis
In an ironic twist of fate, a medication that was able to capitalize on the sinking fortunes of Avandia has itself become entangled with its own set of potential dangers. In a recent Actos lawsuit, William R. Greenlee and his spouse started the New Year ...
Read moreStarting the New Year with Actos Bladder Cancer Lawsuit
The F.D.A. has become more cautious about diabetes drugs in part because of studies linking Avandia, a widely used diabetes drug from GlaxoSmithKline, to a possible increased risk of heart attacks.
Read moreF.D.A. Delays Approval of New Diabetes Drug
The Type 2 diabetes drug was released as an alternative to Avandia, which came in as the fourth most popular heart lawsuit topic. Paxil, a popular antidepressant, has been linked to heart birth defects in infants and garnered 18 percent of traffic last year.
Read moreLawyersandSettlements.com Recognizes American Heart Month With Its Top 10 Heart Lawsuit Topics for 2011
The company will lose patent rights for two of its key drugs, Advair and Avandia, at the end of 2012 but it has a strong phase clinical research pipeline. One such drug is Benlysta (belimumab), in partnership with Human Genome Sciences (HGSI).
Read moreGlaxoSmithKline Poised To Break 52-Week High
Bristol-Myers, based in New York, and London-based AstraZeneca remain committed to the drug, they said. The decision reflects the heightened regulatory scrutiny of diabetes pills since GlaxoSmithKline Plc’s Avandia was tied to heart attacks in ...
Read more